Singapore markets closed

Cronos Group Inc. (CRON)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.9400-0.1400 (-4.55%)
At close: 04:00PM EDT
2.9900 +0.05 (+1.70%)
After hours: 04:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.0800
Bid2.9400 x 1000
Ask2.9500 x 21500
Day's range2.9350 - 3.0600
52-week range2.5700 - 6.7900
Avg. volume2,082,500
Market cap1.12B
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • CNW Group

    Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group

    Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora"), the Canadian company defining the future of cannabinoids worldwide, together with 22nd Century Group, Inc. (NASDAQ: XXII) ("22nd Century") announced today a three-way non-exclusive agreement to license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group"), intended to assist in the advancement of research and development on the biosynthesis of cannabinoids.

  • Business Wire

    Lost Money in Cronos Group, Inc?

    OAKLAND, Calif., December 04, 2021--Shares of Cronos Group plummeted more than 15% on November 9, 2021, after the company announced in an SEC filing that it should have taken an impairment charge of at least $220 million, and that the company would be required to restate its financial statements for three and six months ending June 30, 2021. Gibbs Law Group continues to investigate a potential Cronos Securities Class Action Lawsuit on behalf of investors who lost money in Cronos (NASDAQ: CRON).

  • Business Wire

    CRONOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cronos Group Inc. on Behalf of Cronos Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, November 18, 2021--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON) on behalf of Cronos stockholders. Our investigation concerns whether Cronos has violated the federal securities laws and/or engaged in other unlawful business practices.